The prevalence of KIAA1199 promoter demethylation in breast tumors is strongly consistent with the enhanced expression of KIAA1199 in human breast cancer tissues and aggressive breast cancer cell lines (Figs. 1 and 7E). Here, CEMIP is linked to breast carcinoma.